Welcome to our dedicated page for ChromaDex Corporation news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on ChromaDex Corporation stock.
ChromaDex Corporation (NASDAQ: CDXC) is a pioneering global nutraceutical company dedicated to enhancing healthy aging through scientific advancements. The company's mission revolves around improving the way people age by focusing on the potential of nicotinamide adenine dinucleotide (NAD+), a critical coenzyme in metabolic processes that declines with age.
ChromaDex's team of scientists partners with renowned universities and research institutions worldwide to explore and develop innovative, science-based ingredients. Their flagship product, Tru Niagen®, is a supplement that features Niagen® (nicotinamide riboside), an NAD+ precursor aimed at promoting better aging. Alongside Tru Niagen®, ChromaDex's product portfolio includes PteroPure® (pterostilbene), PureEnergy® (a caffeine-pterostilbene co-crystal), and Anthorigin™ (anthocyanins).
The company operates through three primary segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The majority of ChromaDex's revenue is generated from its Consumer Products segment, driven by the popularity and efficacy of Tru Niagen®.
ChromaDex's commitment to scientific research is evident in its numerous collaborations with academic institutions. These partnerships aim to uncover the full potential of NAD+ and other beneficial compounds to develop products that support health and longevity.
The company's stock is publicly traded on NASDAQ under the symbol CDXC. For more information on ChromaDex, visit their website at www.chromadex.com, follow them on Twitter @chromadex, or like their Facebook page here.
Recent Achievements and Current Projects:
- Continued research and development into NAD+ and its related compounds.
- Expansion of Tru Niagen® into new markets globally.
- Ongoing partnerships with leading universities and research institutions.
- Innovative new product launches aimed at further promoting healthy aging.
ChromaDex Corp. (NASDAQ:CDXC) will hold a conference call on August 3, 2021, at 4:30 p.m. ET to discuss its Q2 financial results ending June 30, 2021. The financial results will be released after the market closes on the same day. Interested participants should join 10 minutes early. The call will also provide a general business update. A replay will be available after the call. ChromaDex specializes in healthy aging and is known for its NAD+ precursor, nicotinamide riboside (Niagen®), featured in its Tru Niagen® product.
ChromaDex Corp. (NASDAQ:CDXC) announced results from four preclinical studies on nicotinamide riboside (NR), showcasing its benefits for healthy aging. Through its ChromaDex External Research Program (CERP™), the company has established over 225 research agreements, leading to 12 clinical and 66 preclinical studies. Notable findings include NR's role in preventing bone loss in aging mice and restoring metabolic capacity in aged stem cells. Additionally, NR is shown to reduce neuroinflammation and mitigate alcohol's harmful effects. ChromaDex has invested over $35 million in NR research and holds over 20 patents.
ChromaDex Corp. (NASDAQ:CDXC) has launched its flagship product, Tru Niagen®, in Walmart, making it available in 3,800 stores across the U.S. This marks Walmart as the first major U.S. retailer to stock the clinically studied NAD+ booster. Customers can choose between 100mg and 300mg serving sizes, both available for in-store and online purchases. Tru Niagen® aims to elevate NAD+ levels, which decline with age, by up to 50%. The product is supported by extensive safety and efficacy research and is recognized by multiple health authorities.
ChromaDex reported Q1 2021 net sales of $14.7 million, a 2% increase year-over-year, driven by a 12% growth in Tru Niagen® sales. The gross margin improved to 62.9%, up 500 basis points. However, the company posted a net loss of $7.4 million, or $0.12 per share, a deeper loss compared to Q1 2020's $5.9 million net loss. Operating expenses rose to $16.6 million, primarily due to increased selling and marketing costs. Looking ahead, ChromaDex anticipates steady revenue growth and continued margin improvement, with new strategic partnerships expected to boost sales.
ChromaDex Corp. (NASDAQ:CDXC) has entered into a strategic supply agreement for its patented ingredient Niagen® with Ro, a healthcare technology company. This agreement gives Ro rights to use Niagen® in specially formulated products aimed at promoting healthy aging. Niagen® is known to increase NAD+ levels, which decline with age. Both companies expressed enthusiasm about the partnership, with ChromaDex's focus on advancing health through research on nicotinamide adenine dinucleotide (NAD+).
ChromaDex Corp. (NASDAQ: CDXC) will participate in a virtual presentation at the Benzinga Small Cap Conference on May 13, 2021, at 11:30am ET. CEO Rob Fried will present on a panel discussing longevity science at 1:20pm ET. This conference aims to connect small-cap companies with investors. ChromaDex's presentation will be available for replay on their investor relations website. The company is known for its research in healthy aging and its flagship product, Niagen®, which supports NAD+ levels that decline with age.
ChromaDex Corp. (NASDAQ:CDXC) will announce its first-quarter financial results for 2021 on May 6, 2021, with a conference call scheduled at 4:30 p.m. ET. The results will be released after market hours on the same day. Investors can access the call via a toll-free number or through the webcast link. ChromaDex is focused on healthy aging research and is known for its NAD+ precursor, nicotinamide riboside (NR), used in its flagship product, Tru Niagen®. The company emphasizes its commitment to innovation and growth.
ChromaDex Corp. (NASDAQ:CDXC) has appointed Fadi Karam as the new Chief Marketing Officer. Karam brings extensive experience in driving consumer businesses and direct-to-consumer operations. He previously led a brand portfolio for Nestlé Waters North America, managing over $3 billion in revenues, and was pivotal in global brand strategies. ChromaDex's CEO, Rob Fried, expressed confidence in Karam's ability to contribute to the growth of the company's flagship product, Tru Niagen®. Karam is enthusiastic about enhancing the brand's reach and impact.
ChromaDex Corp. (NASDAQ: CDXC) has initiated a research partnership with the Citrin Foundation of Singapore to investigate the effects of Niagen® nicotinamide riboside (NR) on citrin deficiency, a rare genetic disorder. Funded studies will focus on how increased NAD+ levels could impact mitochondrial function, inflammation, and liver conditions in affected patients. Lead research will be conducted at Duke-NUS Medical School, aiming to deepen understanding of both citrin deficiency and NAD+ roles in metabolic health.
ChromaDex Corp. (NASDAQ:CDXC) announced that CEO Rob Fried and CFO Kevin Farr will present at the Lytham Partners Spring 2021 Investor Conference.
The presentation is scheduled for March 31, 2021, at 10:15 a.m. ET. Investors can watch the live webcast via the company's website or directly through the provided link.
Additionally, management will engage in virtual one-on-one meetings during the event from March 30 to April 1, 2021, with arrangements managed through Lytham Partners.
FAQ
What is the current stock price of ChromaDex Corporation (CDXC)?
What is the market cap of ChromaDex Corporation (CDXC)?
What is ChromaDex Corporation's main focus?
What is Tru Niagen®?
How does ChromaDex generate most of its revenue?
On which stock exchange is ChromaDex traded?
What are some of ChromaDex's other products?
Who are ChromaDex's research partners?
What is NAD+?
Where can I find more information about ChromaDex?
Does ChromaDex offer services apart from consumer products?
How is ChromaDex contributing to healthy aging research?
